| $337M | ||
| $259M | ||
| $100M | ||
| $79M | ||
| $60M | ||
| $58M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
Over the last 12 months, insiders at MEI Pharma, Inc. have bought $0 and sold $0 worth of MEI Pharma, Inc. stock.
On average, over the past 5 years, insiders at MEI Pharma, Inc. have bought $1.07M and sold $100,625 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 48,060 shares for transaction amount of $329,331 was made by Anson Funds Management LP (10 percent owner) on 2023‑09‑22.
| 2023-09-22 | Anson Funds Management LP | 10 percent owner | 48,060 0.6547% | $6.85 | $329,331 | -34.64% | ||
| 2023-09-22 | Funicular Funds, LP | 10 percent owner | 32,040 0.4364% | $6.85 | $219,554 | -34.64% | ||
| 2023-09-21 | Anson Funds Management LP | 10 percent owner | 33,600 0.4922% | $6.46 | $217,110 | -25.49% | ||
| 2023-09-21 | Funicular Funds, LP | 10 percent owner | 22,400 0.3281% | $6.46 | $144,740 | -25.49% | ||
| 2023-09-20 | Anson Funds Management LP | 10 percent owner | 120,000 1.7317% | $6.01 | $721,116 | -20.72% | ||
| 2023-09-20 | Funicular Funds, LP | 10 percent owner | 80,000 1.1544% | $6.01 | $480,744 | -20.72% | ||
| 2023-02-28 | Baltic Charles V. III | director | 81,500 0.0619% | $0.23 | $18,338 | +54.68% | ||
| 2021-02-23 | Sale | DRISCOLL FREDERICK W | director | 25,000 0.0011% | $4.03 | $100,625 | -29.33% | |
| 2019-12-19 | GOLD DANIEL P PHD | Chief Executive Officer | 18,750 0.0011% | $1.60 | $30,000 | +54.47% | ||
| 2019-12-19 | DRISCOLL FREDERICK W | director | 62,500 0.0035% | $1.60 | $100,000 | +54.47% | ||
| 2019-12-19 | Drazba Brian G. | Chief Financial Officer | 12,500 0.0007% | $1.60 | $20,000 | +54.47% | ||
| 2019-12-19 | Reynolds Thomas C | director | 10,000 0.0006% | $1.60 | $16,000 | +54.47% | ||
| 2019-09-06 | White Christine Anna | director | 15,000 0.001% | $1.74 | $26,075 | +32.37% | ||
| 2018-08-07 | Sale | Urso David M | Chief Operating Officer & GC | 9,500 0.0007% | $3.58 | $34,044 | -17.86% | |
| 2017-11-27 | Sale | Baltic Charles V. III | director | 11,000 0.0015% | $2.21 | $24,272 | +38.58% | |
| 2017-11-27 | Baltic Charles V. III | director | 11,000 0.0015% | $2.25 | $24,801 | +38.58% | ||
| 2015-11-09 | Sale | VIVO VENTURES VII, LLC | 10 percent owner | 314,704 0.0465% | $1.75 | $550,732 | -15.68% | |
| 2015-11-09 | Sale | Vivo Ventures V, LLC | 10 percent owner | 18,284 0.0027% | $1.75 | $31,997 | -15.68% | |
| 2015-11-06 | Sale | VIVO VENTURES VII, LLC | 10 percent owner | 15,120 0.0023% | $1.85 | $27,972 | -19.56% | |
| 2015-11-06 | Sale | Vivo Ventures V, LLC | 10 percent owner | 880 0.0001% | $1.85 | $1,628 | -19.56% |
| NOVOGEN LTD | 10 percent owner | 52408295 786.5736% | $310.26M | 1 | 0 | |
| VIVO VENTURES VII, LLC | 10 percent owner | 3163105 47.4737% | $18.73M | 0 | 11 | |
| Anson Funds Management LP | 10 percent owner | 864188 12.9702% | $5.12M | 3 | 0 | <0.0001% |
| Funicular Funds, LP | 10 percent owner | 460840 6.9165% | $2.73M | 3 | 0 | <0.0001% |
| GOLD DANIEL P PHD | Chief Executive Officer | 361632 5.4276% | $2.14M | 1 | 0 | +54.47% |
| Vivo Ventures V, LLC | 10 percent owner | 183767 2.7581% | $1.09M | 0 | 11 | |
| Baltic Charles V. III | director | 105750 1.5872% | $626,040.00 | 10 | 1 | +32.53% |
| DRISCOLL FREDERICK W | director | 37500 0.5628% | $222,000.00 | 1 | 1 | +54.47% |
| Drazba Brian G. | Chief Financial Officer | 37500 0.5628% | $222,000.00 | 1 | 0 | +54.47% |
| Urso David M | Chief Operating Officer & GC | 24106 0.3618% | $142,707.52 | 0 | 1 | |
| Rueckert William Dodge | director | 20849 0.3129% | $123,426.08 | 4 | 1 | |
| White Christine Anna | director | 15000 0.2251% | $88,800.00 | 1 | 0 | +32.37% |
| JOHNSTON PHILIP A | director | 10000 0.1501% | $59,200.00 | 1 | 0 | |
| Reynolds Thomas C | director | 10000 0.1501% | $59,200.00 | 1 | 0 | +54.47% |
| NAUGHTON CHRISTOPHER | CEO & President | 5000 0.075% | $29,600.00 | 2 | 0 | |
| SEATON DAVID R | CFO & Secretary | 5000 0.075% | $29,600.00 | 1 | 0 | |
| Williams Bryan | director | 5000 0.075% | $29,600.00 | 1 | 0 | |
| New Leaf Ventures II, L.P. | 10 percent owner | 0 0% | $0 | 0 | 10 |
$14,315,062 | 61 | -6.21% | $40.73M | |
$77,062,892 | 41 | 13.96% | $43.89M | |
$22,323,743 | 39 | 23.92% | $31.78M | |
$23,895,365 | 34 | -37.28% | $34.31M | |
$459,011,221 | 33 | 33.04% | $43.97M | |
$167,476,357 | 20 | -1.54% | $44.42M | |
MEI Pharma, Inc. (MEIP) | $2,553,853 | 17 | 16.69% | $39.44M |
$20,234,041 | 17 | 2.09% | $33.26M | |
$36,557,692 | 17 | 3.38% | $33.19M | |
$11,247,055 | 15 | -26.49% | $40.54M | |
$19,300,035 | 11 | 45.88% | $31.78M | |
$31,978,951 | 10 | -70.03% | $37.39M | |
$119,676,458 | 9 | -37.15% | $38.76M | |
$5,524,590 | 7 | 7.40% | $39.11M | |
$5,269,662 | 7 | -11.38% | $42.06M | |
$43,326,461 | 6 | 16.01% | $44.17M | |
$149,996 | 5 | 16.26% | $36.66M | |
$67,369,250 | 3 | -22.09% | $42.33M | |
$150,000 | 1 | 5.48% | $43.03M |
| Increased Positions | 7 | +18.92% | 17,309 | +0.64% |
| Decreased Positions | 11 | -29.73% | 52,806 | -1.95% |
| New Positions | <1 | New | 150 | New |
| Sold Out Positions | 2 | Sold Out | 10,746 | Sold Out |
| Total Postitions | 33 | -10.81% | 3M | -1.31% |
| Anson Funds Management Lp | $2,225.00 | 15.62% | 1.09M | +<1 | 0% | 2024-12-31 |
| Cable Car Capital, Lp | $1,244.00 | 8.74% | 611,440 | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $785.00 | 5.51% | 385,728 | 0 | 0% | 2024-12-31 |
| Renaissance Technologies Llc | $275.00 | 1.93% | 134,946 | -2,700 | -1.96% | 2024-12-31 |
| Acadian Asset Management Llc | $206.00 | 1.45% | 101,313 | -31,049 | -23.46% | 2024-12-31 |
| Blackrock, Inc. | $135.00 | 0.95% | 66,506 | 0 | 0% | 2025-03-31 |
| Geode Capital Management, Llc | $120.00 | 0.85% | 59,207 | -95 | -0.16% | 2024-12-31 |
| Citadel Advisors Llc | $75.00 | 0.52% | 36,665 | +36,665 | New | 2024-12-31 |
| Northern Trust Corp | $72.00 | 0.51% | 35,596 | +12,561 | +54.53% | 2024-12-31 |
| Macquarie Group Ltd | $61.00 | 0.43% | 29,999 | 0 | 0% | 2024-12-31 |